Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR439794 in Peanut Allergic Patients
NCT03463135Phase 1Completed
- Sponsor
- Sanofi
- Start
- May 2018
- Primary completion
- May 2019
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAR439794 in peanut allergy (3 arms), sponsored by Sanofi. Primary endpoint: Adverse events (AEs). Started May 2018; status: completed.
02
Drugs
SAR439794
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03463135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463135.